PFE Jan 2024 25.000 put
| Previous Close | 0.1400 |
| Open | 0.1500 |
| Bid | 0.1200 |
| Ask | 0.1500 |
| Strike | 25.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.1400 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 18.82k |
Yahoo FinanceNext-generation mRNA vaccines will be easier to use: Moderna CEO
Moderna CEO Stéphane Bancel says the company is working on a vaccine formula and packaging that will make it easier to use mNRA technology.
Business WirePfizer Declares Fourth-Quarter 2023 Dividend
NEW YORK, October 04, 2023--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common Stock of record at the close of business on November 10, 2023. The fourth-quarter 2023 cash dividend will be the 340th consecutive quarterly dividend paid by Pfizer.
- Reuters
US plans shift of Merck COVID treatment to commercial market
The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead. The Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services, said in a statement posted on its website late last week they anticipate transition of the drug, sold under the brand name Lagevrio, from government-managed to traditional commercial distribution in November. Merck, which developed the drug with Ridgeback Biotherapeutics, said in an emailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially.
